Angiotensin-(1-7) inhibits vascular remodelling in rat jugular vein grafts via reduced ERK1/2 and p38 MAPK activity

Journal of International Medical Research

Volumn 39, Issue 6, 2011, Pages 2158-2168

  Wu, J G ^a   Tang, H ^a   Liu, Z J ^a   Ma, Z F ^a   Tang, A L ^a   Zhang, X J ^a   Gao, X R ^a   Ma, H ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiotensin (1 7); Coronary artery bypass graft; Kinases; Vascular remodelling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; ANGIOTENSIN[1-7]; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; AUTOGRAFT; BLOOD VESSEL WALL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERPLASIA; INTIMA; MALE; MORPHOLOGY; NONHUMAN; PROTEIN EXPRESSION; RAT; TISSUE LEVEL; VASCULAR DISEASE; VASCULAR REMODELLING; VASCULAR TISSUE; VEIN GRAFT; VENOUS GRAFT HYPERPLASIA;

EID: 84555204265     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900612     Document Type: Article

References (34)

1. Allaire E, Clowes AW: Endothelial cell injury in cardiovascular surgery: the intimal 3 hyperplastic response. Ann Thorac Surg 1997; 63: 582-591.
2. Chaux A, Ruan XM, Fishbein MC, et al: 4 Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998; 115: 604-614.
3. Ferreira AJ, Santos RAS: Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005; 38: 499-507.
4. Wang HQ, Bai L, Shen BR, et al: Coculture with endothelial cells enhances vascular smooth muscle cell adhesion and spreading via activation of β1-integrin and phosphatidylinositol 3-kinase/Akt. Eur J Cell Biol 2007; 86: 51-62.
5. Freeman EJ, Chisolm GM, Ferrario CM, et al: Calmodulin-dependent protein phosphatase: immunocytochemical localization in chick retina. Hypertension 1996; 28: 104-108.
6. Gallagher PE, Tallant EA: Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004; 25: 2045-2052.
7. Yu PJ, Ferrari G, Pirelli L, et al: Vascular injury and modulation of MAPKs: a targeted approach to therapy of restenosis. Cell Signal 2007; 19: 1359-1371.
8. Jeremy JY, Dashwood MR, Timm M, et al: Nitric oxide synthase and adenylyl and guanylyl cyclase activity in porcine interposition vein grafts. Ann Thorac Surg 1997; 63: 470-476.
9. Wallitt E, Jevon M, Hornick PI: Therapeutics of vein graft intimal hyperplasia: 100 years on. Ann Thorac Surg 2007; 84: 317-323.
10. Koyama H, Olson NE, Dastvan FF, et al: Cell replication in the arterial wall: activation of signalling pathway following in vivo injury. Circ Res 1998; 82: 713-721.
11. Kucharewicz I, Pawlak R, Matys T, et al: Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002; 40: 774-779.
12. Langeveld B, van Gilst WH, Tio RA, et al: Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005; 45: 138-141.
13. Liu B, Fisher M, Groves P: Down-regulation of the ERK1 and ERK2 mitogen-activated protein kinases using antisense oligonucleotides inhibits intimal hyperplasia in a porcine model of coronary balloon angioplasty. Cardiovasc Res 2002; 54: 640-648.
14. Matsumoto T, Komori K, Yonemitsu Y, et al: Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 1998; 27: 135-144.
15. Pawashe AB, Golino P, Ambrosio G, et al: A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74: 56-63.
16. Kucharewicz I, Chabielska E, Pawlak D, et al: The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. J Renin Angiotensin Aldosterone Syst 2000; 1: 268-272.
17. Nakashima H, Suzuki H, Ohtsu H, et al: Angiotensin II regulates vascular and endothelial dysfunction: recent topics of angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol 2006; 4: 67-78.
18. Nwasokwa ON: Coronary artery bypass graft disease. Ann Intern Med 1995; 123: 528-533.
19. O'Brien JE Jr, Shi Y, Fard A, et al: Wound healing around and within saphenous vein bypass grafts. J Thorac Cardiovasc Surg 1997; 114: 38-45.
20. American Society of Mammalogists: Guidelines for the capture, handling, and care of mammals as approved by the American Society of Mammalogists. J Mammal 1988 79: 1416-1431.
21. Strawn WB, Ferrario CM, Tallant EA, et al: Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
22. Leask RL, Butany J, Johnston KW, et al: Human saphenous vein coronary artery bypass graft morphology, geometry and hemodynamics. Ann Biomed Eng 2005; 33: 301-309.
23. Grondin CM, Meere C, Castonguay Y, et al: Progressive and late obstruction of an aortocoronary venous bypass graft. Circulation 1971; 43: 698-702.
24. Pintucci G, Froum S, Pinnell J, et al: Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost 2002; 88: 834-842.
25. Ren Y, Garvin JL, Carretero OA: Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 2002; 39: 799-802.
26. Sampaio WO, Henrique de Castro C, Santos RA, et al: Angiotensin-(1-7) counter-regulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-1098.
27. Tallant EA, Clark MA: Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42: 574-579.
28. Santos RA, Campagnole-Santos MJ, Andrade SP: Angiotensin-(1-7): an update. Regul Pept 2000; 91: 54-62.
29. Shuhaiber JH, Evans AN, Massad MG, et al: Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg 2002; 22: 387-396.
30. Wang X, Tournier C: Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 2006; 18: 753-760.
31. Saunders PC, Pintucci G, Bizekis CS, et al: Vein graft arterialization causes differential activation of mitogen-activated protein kinases. J Thorac Cardiovasc Surg 2004; 127: 1276-1284.
32. Verdecchia P, Angeli F, Mazzotta G, et al: The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 2008; 4: 971-981.
33. Nie W, Yan H, Li S, et al: Angiotensin-(1-7) enhances angiotensin II-induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. Mol Immunol 2009; 46: 355-361.
34. Giani JF, Muñoz MC, Mayer MA, et al: Angiotensin-(1-7) improves cardiac remodeling and inhibits growth promoting pathways in the heart of fructose-fed rats. Am J Physiol Heart Circ Physiol 2010; 298: H1003-H1013.